Has Subramanyeswara Arekapudi received payments from drug or device companies?

Yes. Drug and device makers reported $374,550 in general payments to Subramanyeswara Arekapudi across 320 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Subramanyeswara Arekapudi did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Subramanyeswara Arekapudi come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Subramanyeswara Arekapudi

Hematology & Oncology · Reno, NVNPI 1366671943

Payments from drug & device makers

$374,550in general payments, 2019–2025

Across 320 payments — averaging $1170.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Astrazeneca UK Limited$92K
Pfizer$63K
ADC Therapeutics America, Inc.$44K
E.r. Squibb & Sons, L.L.C.$38K
Genentech, Inc.$35K
Bristol Myers Squibb$33K
plus $71K from 52 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Astrazeneca UK Limited	2	$91,564
Pfizer	15	$62,699
ADC Therapeutics America, Inc.	7	$43,621
E.r. Squibb & Sons, L.L.C.	38	$38,297
Genentech, Inc.	4	$34,813
Bristol Myers Squibb	14	$32,615
Pharmaessentia USA Corporation	6	$20,129
Karyopharm Therapeutics Inc.	4	$18,884
Eisai Inc.	18	$11,843
Incyte Corporation	12	$6,580
AbbVie	6	$4,112
EMD Serono, Inc.	6	$3,887
AstraZeneca(2 entities)	24	$681
Sanofi	8	$327
Seagen Inc.	12	$325
Regeneron Healthcare Solutions, Inc.	6	$261
Gilead	4	$256
Blueprint Medicines Corporation	2	$246
GSK	8	$216
Exelixis Inc.	6	$201
Merck	9	$200
Astellas Pharma US Inc	3	$196
Daiichi Sankyo Inc.	9	$195
Pharmacyclics LLC, An Abbvie Company	7	$193
Genentech USA, Inc.	8	$192
Beigene USA, Inc.	3	$165
Johnson & Johnson	7	$159
Novartis	7	$144
Takeda Pharmaceuticals U.S.A., Inc.	4	$117
Tempus AI, Inc	4	$95
Sanofi-aventis U.S. LLC	1	$95
Amgen	3	$89
Springworks Therapeutics, Inc.	3	$88
Deciphera Pharmaceuticals Inc.	4	$88
Mirati Therapeutics, Inc.	3	$70
Acrotech Biopharma Inc.	4	$64
Boehringer Ingelheim	2	$63
Taiho Oncology, Inc.	3	$62
Array Biopharma Inc	2	$57
Kyowa Kirin, Inc.	2	$56
AVEO Pharmaceuticals, Inc.	2	$55
Organon	3	$55
Servier Pharmaceuticals LLC	2	$47
Apellis Pharmaceuticals, Inc.	2	$46
Bayer	2	$41
Lilly USA, LLC	2	$40
Jazz Pharmaceuticals Inc.	2	$38
Tersera Therapeutics LLC	1	$38
Sobi, Inc	2	$37
Ipsen Biopharmaceuticals, Inc	2	$36
Spectrum Pharmaceuticals Inc.	1	$34
Octapharma USA, Inc.	2	$31
Tactile Systems Technology Inc	2	$28
Agios Pharmaceuticals, Inc.	1	$22
Coherus Oncology, Inc.	1	$18
Myriad Genetic Laboratories, Inc.	1	$14
EUSA Pharma (US) LLC	1	$14
G1 Therapeutics, Inc.	1	$14

How this compares

$374,550 in reported general payments places this provider in the 85th percentile of 82 hematology & oncology providers in Nevada.

See all hematology & oncology providers in Nevada →

Medicare billing

Part B allowed, 2024

$1,659,535

Medicare patients

642

Services billed

65,531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Reno

See the full list for Nevada →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →